Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, The Equitable Community Access to Pharmacist Services Act. Issues related to drug distribution and access. Issues related to the reauthorization of the Pandemic and All Hazards Preparedness Act.
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
Duration: April 18, 2018
to
present
General Issues: Health Issues , Pharmacy , Defense , Animals
Spending: about $1,420,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2018: U.S. Senate, House of Representatives, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Lori Denham
Chief of Staff, Legislative Director, Legislative Assistant, Senior Policy Advisor, Communications Director, Staff Assistant - Rep. Cal Dooley, D-CA; Legislative Director - Rep. Darlene Hooley, D-OR.
Julie Hershey Carr
Senior Policy Advisor, Legislative Director, Legislative Assistant - Rep. Joe Pitts, R-PA.
Lisa Kountoupes
Deputy Asst. to the President&House Liaison, Special Assistant to the President for Legislative Affairs, Asst. Director for Legislative Affairs at OMB, Special Asst. to Undersecretary,Dept.of Energy,Policy Advisor to Chairman of Energy&Commerce Comm.
David Peluso
Chief of Staff - Representative Cathy McMorris Rodgers, R-WA; Chief of Staff, Communications Director, Legislative Assistant, Deputy Press Secretary and Executive Assistant - Representative Gus Bilirakis, R-FL.
Rose Sullivan
Chief of Staff, Legislative Director, Legislative Assistant, Outreach Director, Constituent Services Advocate - Sen. Amy Klobuchar, D-MN
Patrick Hayes
Chief of Staff, Legislative Director - Sen. Joe Manchin, D-WV; Deputy Legislative Director, Legislative Assistant - Sen. Evan Bayh, D-IN; Staff Director - Senate Democratic Steering and Outreach Committee.
Mary Dee Beal
Policy Analyst,Senate Republican Policy Committee;Acting Chief of Staff to the Deputy Secretary,USDA;Senior Advisor to the Secretary,USDA;Legislative Director,Cong. Drew Ferguson,R-GA; Legis. Director, Legis. Assistant, Scheduler Cong. Austin Scott,R
Leslie Zelenko
Deputy Assistant Secretary for Legislation, Senior Advisor/Congressional Liaison-HHS; Legislative Director,Senior Legislative Assistant,Legislative Assistant,Legislative Correspondent-Cong. Mark Pocan, D-WI; Staff Assistant-Cong. Tammy Baldwin, D-WI
Denise Mousouris
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for Cencora Inc. (formerly AmerisourceBergen Corporation) , earning $60,000. The report was filed on April 9.
Original Filing: 301547562.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, The Equitable Community Access to Pharmacist Services Act. Issues related to drug distribution and access. Issues related to the reauthorization of the Pandemic and All Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
4th Quarter, 2023
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for Cencora Inc. (formerly AmerisourceBergen Corporation) , earning $60,000. The report was filed on Jan. 12.
Original Filing: 301523804.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, The Equitable Community Access to Pharmacist Services Act. Issues related to drug distribution and access. Issues related to the reauthorization of the Pandemic and All Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
3rd Quarter, 2023
Kountoupes Denham Carr & Reid, LLC amended a lobbying report for representation of Cencora Inc. (formerly AmerisourceBergen Corporation) in Q32023 on Dec. 13, 2023.
Original Filing: 301520488.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, The Equitable Community Access to Pharmacist Services Act. Issues related to drug distribution and access. Issues related to the reauthorization of the Pandemic and All Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for Cendora Inc. (formerly AmerisourceBergen Corporation) , earning $60,000. The report was filed on Oct. 12, 2023.
Original Filing: 301499900.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S.2477, The Equitable Community Access to Pharmacist Services Act. Issues related to drug distribution and access. Issues related to the reauthorization of the Pandemic and All Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Issues related to drug pricing transparency. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770/S. 2477, The Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on July 13, 2023.
Original Filing: 301475875.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770, The Equitable Community Access to Pharmacist Services Act. Issues related to drug distribution and access. Issues related to the reauthorization of the Pandemic and All Hazards Preparedness Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 1770, The Equitable Community Access to Pharmacist Services Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on April 19, 2023.
Original Filing: 301456931.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Jan. 18, 2023.
Original Filing: 301431178.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to the supply chain provisions in S. 3799, PREVENT Pandemics Act. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to Monkeypox vaccine and treatment distribution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense, including H.R. 7900, National Defense Authorization Act for Fiscal Year 2023.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Oct. 18, 2022.
Original Filing: 301407751.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to the supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to pharmacy provider status. Issues related to drug pricing in the Inflation Reduction Act (Public Law 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to Monkeypox vaccine and treatment distribution. Issues related to drug pricing in the Inflation Reduction Act (Public Law 117-169).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug shortages and stockpile issues at the U.S. Department of Defense, including H.R. 7900, National Defense Authorization Act for Fiscal Year 2023.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on July 19, 2022.
Original Filing: 301384983.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages and national stockpile issues, including H.R.2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to pharmacy provider status. Issues related to the budget reconciliation process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to the budget reconciliation process.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to drug shortages and stockpile issues at the Department of Defense including H.R. 7900 - National Defense Authorization Act for Fiscal Year 2023.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on April 18, 2022.
Original Filing: 301358899.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain, drug shortages and national stockpile issues, including H.R.2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to pharmacy provider status. Issues related to H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to drug pricing in H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to drug shortages and stockpile issues at the Department of Defense.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331177.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain including proposals that would address drug shortages and national stockpile issues, including H.R.2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status. Issues related to H.R. 5067, Preserving Access to Home Infusion Act. Issues related to H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status. Issues related to oncology medicines in H.R. 5067, the Preserving Patient Access to Home Infusion Act. Issues related to drug pricing in H.R. 5376, the Build Back Better Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Issues related to drug shortages and stockpile issues at the Department of Defense. Issues related to pharmaceutical provisions in S.1605, the National Defense Authorization Act for Fiscal Year 2022.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Oct. 18, 2021.
Original Filing: 301302505.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain including proposals that would address drug shortages and national stockpile issues, including H.R.2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status. Issues related to H.R. 5067, Preserving Access to Home Infusion Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status. Issues related to oncology medicines in H.R. 5067, the Preserving Patient Access to Home Infusion Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP) Health & Human Services - Dept of (HHS) Office of Management & Budget (OMB)
Lobbying Issues
Issues related to drug shortages and stockpile issues at the Department of Defense. Issues related to pharmaceutical provisions in H.R. 4350, the National Defense Authorization Act for Fiscal Year 2022.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301285170.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain including proposals that would address drug shortages and national stockpile issues, including H.R.2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to the implementation of H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Executive Office of the President (EOP)
Lobbying Issues
Issues related to drug shortages and stockpile issues at the Department of Defense.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301261991.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain including proposals that would address drug shortages and national stockpile issues. Issues related to sequestration relief. Issues related to COVID-19 testing and essential worker designation. Issues related to H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to proposals that would address drug shortages and national stockpile issues. Issues related to COVID-19 vaccine distribution. Issues related to H.R. 1319, the American Rescue Plan. Issues related to pharmacy provider status.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236079.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to the implementation of PL 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including those related to the drug supply chain. Issues related to H.R. 6800, the HEROES Act. Issues related to providing specialty physicians relief due to the financial strain caused by COVID-19. Issues related to pharmacy provider status. Issues related to sequestration delay extension. Issues related to H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to the implementation of PL 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions. Issues related to H.R. 6800, the Heroes Act. Issues related to proposals that would address drug shortages and national stockpile issues. Issues related to COVID-19 vaccine distribution.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Oct. 13, 2020.
Original Filing: 301209329.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to the implementation of PL 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including those related to the drug supply chain. Issues related to H.R. 6800, the HEROES Act. Issues related to S.1903, the Advancing Emergency Preparedness Through One Health Act of 2019, including those related to zoonotic diseases. Issues related to providing specialty physicians relief due to the financial strain caused by COVID-19. Issues related to pharmacy provider status. Issues related to sequestration delay extension.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to the implementation of PL 116-136, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions. Issues related to H.R. 6800, the Heroes Act. Issues related to proposals that would address drug shortages and national stockpile issues.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301196012.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act. Issues related to the implementation of H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including those related to the drug supply chain. Issues related to H.R. 6800, the HEROES Act. Issues related to S.1903, the Advancing Emergency Preparedness Through One Health Act of 2019, including those related to zoonotic diseases. Issues related to providing specialty physicians relief due to the financial strain caused by COVID-19.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to the implementation of H.R.748, Coronavirus Aid,Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions. Issues related to H.R. 6800, the Heroes Act. Issues related to drug shortage proposals.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2020
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on April 17, 2020.
Original Filing: 301169673.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act. Issues related to H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including those related to the drug supply chain.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B. Issues related to H.R.748, Coronavirus Aid,Relief, and Economic Security Act (CARES Act), including Medicare and Medicaid provisions.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2019
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Jan. 17, 2020.
Original Filing: 301110563.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2019
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Oct. 21, 2019.
Original Filing: 301074924.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain. Proposed modifications to the existing definition of distributor bona fide service fees in Medicare Part B.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to the distribution and pricing of medicines for pets.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on July 15, 2019.
Original Filing: 301045535.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of the Drug Quality and Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to drug pricing in the pharmaceutical supply chain.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2019
In Q1, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on April 17, 2019.
Original Filing: 301026979.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including implementation of H. R. 3204, the Drug Quality and Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Jan. 22, 2019.
Original Filing: 301013753.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including H. R. 3204, the Drug Quality and Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $60,000. The report was filed on Oct. 19, 2018.
Original Filing: 300992002.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances. Issues related to pharmaceutical compounding, including H. R. 3204, the Drug Quality and Security Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, Kountoupes Denham Carr & Reid, LLC lobbied for AmerisourceBergen , earning $40,000. The report was filed on July 12, 2018.
Original Filing: 300964336.xml
Lobbying Issues
Issues related to the pharmaceutical supply chain. Issues related to the distribution of opioids and related to the distribution of controlled substances.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate